Letters to the Editor

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg, Germany; Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam
Princess Máxima Center for Pediatric Oncology, Utrecht
Pediatric Hematology, Immunology, Oncology, Sorbonne université, Hôpital Armand Trousseau, APHP, Paris
Pediatrics 5 (Oncology, Hematology, and Immunology), Olgahospital, Stuttgart
Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg
Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Dept. Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Dept. Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht
Princess Máxima Center for Pediatric Oncology, Utrecht
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam
Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg
Princess Máxima Center for Pediatric Oncology, Utrecht
Haematologica Early view Dec 15, 2022 https://doi.org/10.3324/haematol.2022.281896